| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Reperfusion Injury | 21 | 2021 | 320 | 4.280 |
Why?
|
| Lung Transplantation | 9 | 2021 | 88 | 3.550 |
Why?
|
| Heart Transplantation | 14 | 2021 | 328 | 2.860 |
Why?
|
| Nasal Polyps | 9 | 2022 | 184 | 2.180 |
Why?
|
| Receptors, Complement | 11 | 2018 | 58 | 2.130 |
Why?
|
| Recombinant Fusion Proteins | 17 | 2021 | 376 | 2.100 |
Why?
|
| Complement Activation | 20 | 2021 | 145 | 1.980 |
Why?
|
| Complement Inactivating Agents | 7 | 2021 | 56 | 1.640 |
Why?
|
| Brain Death | 5 | 2021 | 34 | 1.620 |
Why?
|
| Sinusitis | 8 | 2019 | 432 | 1.590 |
Why?
|
| Complement System Proteins | 11 | 2020 | 135 | 1.490 |
Why?
|
| Complement C3 | 16 | 2018 | 101 | 1.420 |
Why?
|
| Tissue Donors | 4 | 2023 | 195 | 1.420 |
Why?
|
| Mice, Inbred C57BL | 40 | 2021 | 2791 | 1.380 |
Why?
|
| Autoantibodies | 7 | 2021 | 434 | 1.360 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2021 | 84 | 1.320 |
Why?
|
| Rhinitis | 5 | 2019 | 383 | 1.270 |
Why?
|
| Graft Rejection | 14 | 2023 | 458 | 1.260 |
Why?
|
| Mice | 54 | 2022 | 8474 | 1.250 |
Why?
|
| Mice, Inbred BALB C | 15 | 2021 | 532 | 1.230 |
Why?
|
| Vascularized Composite Allotransplantation | 3 | 2021 | 17 | 1.110 |
Why?
|
| Immunoglobulin M | 6 | 2021 | 172 | 0.990 |
Why?
|
| Animals | 61 | 2022 | 20881 | 0.950 |
Why?
|
| Postoperative Complications | 3 | 2021 | 1615 | 0.930 |
Why?
|
| Lung Injury | 2 | 2021 | 38 | 0.920 |
Why?
|
| Calcitriol | 2 | 2022 | 106 | 0.910 |
Why?
|
| Complement Pathway, Alternative | 7 | 2016 | 69 | 0.900 |
Why?
|
| Epithelial Cells | 6 | 2022 | 431 | 0.890 |
Why?
|
| Primary Graft Dysfunction | 2 | 2021 | 12 | 0.890 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2021 | 199 | 0.870 |
Why?
|
| Antibodies | 5 | 2019 | 241 | 0.850 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 207 | 0.800 |
Why?
|
| Transplants | 2 | 2021 | 28 | 0.770 |
Why?
|
| Single-Chain Antibodies | 3 | 2021 | 15 | 0.740 |
Why?
|
| Receptors, Complement 3b | 9 | 2021 | 35 | 0.730 |
Why?
|
| Inflammation | 5 | 2018 | 1030 | 0.680 |
Why?
|
| Receptors, Complement 3d | 9 | 2015 | 45 | 0.650 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 511 | 0.640 |
Why?
|
| Rhinosporidiosis | 1 | 2018 | 7 | 0.630 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 71 | 0.630 |
Why?
|
| Nasal Mucosa | 5 | 2018 | 68 | 0.620 |
Why?
|
| Disease Models, Animal | 19 | 2021 | 2550 | 0.610 |
Why?
|
| Smoke | 5 | 2017 | 46 | 0.600 |
Why?
|
| Rhinitis, Allergic | 1 | 2017 | 22 | 0.590 |
Why?
|
| Mice, Knockout | 20 | 2020 | 1692 | 0.580 |
Why?
|
| Cholecalciferol | 1 | 2017 | 143 | 0.560 |
Why?
|
| Organ Transplantation | 4 | 2022 | 110 | 0.540 |
Why?
|
| Disease Progression | 2 | 2019 | 1038 | 0.530 |
Why?
|
| Complement Inactivator Proteins | 3 | 2010 | 20 | 0.520 |
Why?
|
| Myocardial Reperfusion | 2 | 2015 | 32 | 0.510 |
Why?
|
| Humans | 53 | 2023 | 68618 | 0.500 |
Why?
|
| Self Tolerance | 1 | 2015 | 8 | 0.500 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2018 | 127 | 0.500 |
Why?
|
| Antibodies, Bispecific | 1 | 2015 | 12 | 0.500 |
Why?
|
| Dendritic Cells | 6 | 2020 | 201 | 0.500 |
Why?
|
| P-Selectin | 3 | 2021 | 16 | 0.500 |
Why?
|
| Epitopes | 4 | 2021 | 146 | 0.470 |
Why?
|
| Graft vs Host Disease | 3 | 2021 | 163 | 0.450 |
Why?
|
| Complement Factor H | 2 | 2010 | 21 | 0.450 |
Why?
|
| Transplantation, Homologous | 7 | 2021 | 242 | 0.430 |
Why?
|
| Rhinitis, Allergic, Perennial | 2 | 2011 | 43 | 0.430 |
Why?
|
| Mycoses | 2 | 2011 | 60 | 0.430 |
Why?
|
| Coronary Artery Disease | 3 | 2010 | 696 | 0.370 |
Why?
|
| Male | 36 | 2021 | 37321 | 0.370 |
Why?
|
| Immunosuppressive Agents | 4 | 2022 | 514 | 0.370 |
Why?
|
| Paranasal Sinuses | 3 | 2019 | 165 | 0.360 |
Why?
|
| Bronchiolitis Obliterans | 4 | 2021 | 15 | 0.350 |
Why?
|
| Liver Regeneration | 3 | 2017 | 38 | 0.350 |
Why?
|
| Complement C3d | 2 | 2010 | 10 | 0.350 |
Why?
|
| Elastin | 2 | 2021 | 116 | 0.350 |
Why?
|
| Complement C3a | 1 | 2009 | 3 | 0.350 |
Why?
|
| Fungi | 1 | 2010 | 27 | 0.350 |
Why?
|
| Smoking | 5 | 2020 | 1452 | 0.340 |
Why?
|
| Hindlimb | 2 | 2021 | 38 | 0.340 |
Why?
|
| Disease Susceptibility | 4 | 2020 | 179 | 0.330 |
Why?
|
| Aspergillus fumigatus | 3 | 2018 | 27 | 0.330 |
Why?
|
| Gene Expression Regulation | 6 | 2020 | 1293 | 0.330 |
Why?
|
| Brain Ischemia | 3 | 2012 | 665 | 0.320 |
Why?
|
| Liver | 5 | 2014 | 1118 | 0.320 |
Why?
|
| Transplantation Tolerance | 2 | 2021 | 13 | 0.320 |
Why?
|
| Eosinophils | 2 | 2019 | 60 | 0.320 |
Why?
|
| Neutrophils | 4 | 2017 | 204 | 0.300 |
Why?
|
| Tunica Intima | 2 | 2005 | 59 | 0.300 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2020 | 132 | 0.300 |
Why?
|
| Tobacco | 4 | 2017 | 161 | 0.290 |
Why?
|
| Retinal Pigment Epithelium | 3 | 2020 | 145 | 0.290 |
Why?
|
| Cytokines | 8 | 2019 | 866 | 0.280 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 170 | 0.270 |
Why?
|
| Lung | 5 | 2011 | 849 | 0.270 |
Why?
|
| Endothelium, Vascular | 5 | 2010 | 371 | 0.270 |
Why?
|
| Hypertension, Pulmonary | 3 | 2005 | 232 | 0.270 |
Why?
|
| Lupus Nephritis | 1 | 2008 | 193 | 0.270 |
Why?
|
| Signal Transduction | 8 | 2021 | 2689 | 0.260 |
Why?
|
| Chronic Disease | 6 | 2019 | 1330 | 0.260 |
Why?
|
| Models, Animal | 3 | 2017 | 252 | 0.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2021 | 266 | 0.250 |
Why?
|
| Communicable Diseases | 1 | 2005 | 50 | 0.250 |
Why?
|
| Intestines | 1 | 2005 | 114 | 0.250 |
Why?
|
| Autoimmune Diseases | 2 | 2021 | 186 | 0.240 |
Why?
|
| Lung Diseases | 2 | 2021 | 175 | 0.240 |
Why?
|
| Endothelial Cells | 3 | 2021 | 384 | 0.240 |
Why?
|
| MicroRNAs | 2 | 2020 | 447 | 0.240 |
Why?
|
| Graft Survival | 4 | 2021 | 465 | 0.240 |
Why?
|
| Immunoglobulin G | 4 | 2021 | 481 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 183 | 0.230 |
Why?
|
| Coronary Vessels | 2 | 2018 | 313 | 0.230 |
Why?
|
| Receptor, Anaphylatoxin C5a | 3 | 2018 | 20 | 0.220 |
Why?
|
| Liver Transplantation | 6 | 2017 | 400 | 0.220 |
Why?
|
| Myocardium | 6 | 2015 | 1204 | 0.220 |
Why?
|
| Vitamin D Deficiency | 2 | 2017 | 292 | 0.220 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 144 | 0.210 |
Why?
|
| Immunohistochemistry | 8 | 2012 | 1174 | 0.210 |
Why?
|
| Mixed Function Oxygenases | 1 | 2022 | 35 | 0.210 |
Why?
|
| Inflammasomes | 1 | 2022 | 39 | 0.210 |
Why?
|
| Cell Adhesion | 2 | 2021 | 324 | 0.210 |
Why?
|
| Cells, Cultured | 5 | 2021 | 2673 | 0.210 |
Why?
|
| Organ Specificity | 3 | 2016 | 167 | 0.200 |
Why?
|
| Mitochondrial Dynamics | 1 | 2021 | 17 | 0.200 |
Why?
|
| Complement C2 | 1 | 2021 | 9 | 0.200 |
Why?
|
| Spinal Cord Injuries | 3 | 2017 | 551 | 0.190 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2008 | 756 | 0.190 |
Why?
|
| Receptor, Endothelin A | 1 | 2021 | 35 | 0.190 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2021 | 80 | 0.190 |
Why?
|
| Glycosylation | 1 | 2021 | 185 | 0.190 |
Why?
|
| Antagomirs | 1 | 2020 | 1 | 0.190 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 35 | 0.190 |
Why?
|
| Kupffer Cells | 2 | 2011 | 75 | 0.190 |
Why?
|
| Chemokine CXCL1 | 1 | 2020 | 21 | 0.190 |
Why?
|
| Energy Metabolism | 2 | 2018 | 222 | 0.180 |
Why?
|
| Death | 1 | 2020 | 38 | 0.180 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 100 | 0.180 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 8 | 0.180 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 18 | 0.180 |
Why?
|
| Microcirculation | 4 | 2013 | 77 | 0.180 |
Why?
|
| Bruch Membrane | 1 | 2020 | 6 | 0.180 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 110 | 0.180 |
Why?
|
| Geographic Atrophy | 1 | 2020 | 5 | 0.180 |
Why?
|
| Kidney Diseases | 2 | 2017 | 307 | 0.180 |
Why?
|
| Cyclosporine | 2 | 2018 | 121 | 0.170 |
Why?
|
| Homeodomain Proteins | 3 | 2017 | 157 | 0.170 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2011 | 114 | 0.170 |
Why?
|
| Polysaccharides | 1 | 2021 | 176 | 0.170 |
Why?
|
| Microdissection | 2 | 2018 | 15 | 0.170 |
Why?
|
| Melanoma | 1 | 2022 | 335 | 0.160 |
Why?
|
| Fatty Liver | 2 | 2009 | 97 | 0.160 |
Why?
|
| Kidney | 2 | 2018 | 945 | 0.160 |
Why?
|
| Cell Line | 3 | 2018 | 1752 | 0.160 |
Why?
|
| Melanoma, Experimental | 2 | 2017 | 95 | 0.160 |
Why?
|
| Survival Rate | 3 | 2013 | 1056 | 0.160 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2018 | 41 | 0.150 |
Why?
|
| Histone Deacetylase 1 | 1 | 2018 | 32 | 0.150 |
Why?
|
| Macular Degeneration | 2 | 2016 | 75 | 0.150 |
Why?
|
| Nasal Lavage | 1 | 2017 | 6 | 0.150 |
Why?
|
| Blood Cell Count | 1 | 2017 | 35 | 0.150 |
Why?
|
| Vitamin D | 1 | 2022 | 516 | 0.150 |
Why?
|
| Proteome | 1 | 2018 | 87 | 0.150 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 187 | 0.150 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2018 | 94 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2008 | 138 | 0.150 |
Why?
|
| Inflammation Mediators | 3 | 2018 | 244 | 0.150 |
Why?
|
| Complement Factor B | 3 | 2014 | 19 | 0.150 |
Why?
|
| Composite Tissue Allografts | 1 | 2017 | 8 | 0.150 |
Why?
|
| Liposomes | 2 | 2015 | 107 | 0.150 |
Why?
|
| Glutamyl Aminopeptidase | 1 | 2017 | 12 | 0.140 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 116 | 0.140 |
Why?
|
| Mesothelioma | 1 | 2017 | 21 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2017 | 228 | 0.140 |
Why?
|
| Adult | 13 | 2018 | 21403 | 0.140 |
Why?
|
| Stroke | 3 | 2015 | 2163 | 0.140 |
Why?
|
| Female | 17 | 2023 | 38074 | 0.140 |
Why?
|
| Complement Pathway, Classical | 2 | 2020 | 22 | 0.140 |
Why?
|
| Tissue Engineering | 1 | 2018 | 212 | 0.140 |
Why?
|
| Cellular Senescence | 1 | 2017 | 112 | 0.130 |
Why?
|
| Wound Healing | 1 | 2018 | 260 | 0.130 |
Why?
|
| Biopsy | 3 | 2013 | 540 | 0.130 |
Why?
|
| Th17 Cells | 1 | 2017 | 116 | 0.130 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 194 | 0.130 |
Why?
|
| Th1 Cells | 2 | 2018 | 101 | 0.130 |
Why?
|
| Gene Targeting | 1 | 2015 | 58 | 0.130 |
Why?
|
| Ischemia | 3 | 2011 | 229 | 0.130 |
Why?
|
| Kidney Glomerulus | 1 | 2017 | 155 | 0.130 |
Why?
|
| Mitochondria | 2 | 2018 | 643 | 0.130 |
Why?
|
| T-Lymphocytes | 4 | 2018 | 597 | 0.130 |
Why?
|
| Long Term Adverse Effects | 1 | 2015 | 6 | 0.130 |
Why?
|
| Annexin A4 | 1 | 2015 | 2 | 0.130 |
Why?
|
| Bronchi | 2 | 2006 | 59 | 0.130 |
Why?
|
| Genes, Synthetic | 1 | 2015 | 5 | 0.130 |
Why?
|
| Warm Ischemia | 2 | 2018 | 8 | 0.130 |
Why?
|
| Neural Tube Defects | 1 | 2015 | 27 | 0.130 |
Why?
|
| Pneumonia | 2 | 2008 | 110 | 0.130 |
Why?
|
| Regeneration | 1 | 2015 | 105 | 0.120 |
Why?
|
| Aorta, Abdominal | 1 | 2015 | 97 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2017 | 332 | 0.120 |
Why?
|
| Recovery of Function | 2 | 2016 | 506 | 0.120 |
Why?
|
| Phospholipids | 1 | 2015 | 108 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 710 | 0.120 |
Why?
|
| Folic Acid | 1 | 2015 | 123 | 0.120 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 1173 | 0.120 |
Why?
|
| Macrophages | 3 | 2018 | 647 | 0.120 |
Why?
|
| Middle Aged | 11 | 2018 | 21147 | 0.120 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 839 | 0.120 |
Why?
|
| Retina | 1 | 2016 | 252 | 0.120 |
Why?
|
| Complex Mixtures | 2 | 2014 | 14 | 0.120 |
Why?
|
| Diet | 1 | 2017 | 514 | 0.120 |
Why?
|
| Respiratory Mucosa | 2 | 2014 | 52 | 0.110 |
Why?
|
| Aorta, Thoracic | 1 | 2015 | 211 | 0.110 |
Why?
|
| Apoptosis | 4 | 2018 | 1641 | 0.110 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2014 | 99 | 0.110 |
Why?
|
| Airway Remodeling | 1 | 2013 | 7 | 0.110 |
Why?
|
| Neutrophil Infiltration | 3 | 2009 | 35 | 0.110 |
Why?
|
| Eye Diseases | 1 | 2013 | 38 | 0.110 |
Why?
|
| Complement C5a | 1 | 2013 | 15 | 0.110 |
Why?
|
| Enterovirus A, Human | 1 | 2012 | 3 | 0.110 |
Why?
|
| Neurogenic Inflammation | 1 | 2012 | 4 | 0.110 |
Why?
|
| In Situ Hybridization | 2 | 2004 | 201 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2011 | 226 | 0.110 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 807 | 0.110 |
Why?
|
| Thrombin | 1 | 2013 | 117 | 0.100 |
Why?
|
| Interleukin-10 | 2 | 2010 | 144 | 0.100 |
Why?
|
| Heart | 2 | 2018 | 850 | 0.100 |
Why?
|
| Lipids | 1 | 2014 | 298 | 0.100 |
Why?
|
| Transplantation, Heterologous | 2 | 2002 | 122 | 0.100 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2011 | 17 | 0.100 |
Why?
|
| Mucin-1 | 2 | 2008 | 35 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2018 | 1664 | 0.100 |
Why?
|
| Trachea | 1 | 2011 | 48 | 0.100 |
Why?
|
| Paraquat | 1 | 2011 | 8 | 0.100 |
Why?
|
| Aspergillosis | 1 | 2011 | 20 | 0.100 |
Why?
|
| Th2 Cells | 1 | 2011 | 48 | 0.100 |
Why?
|
| Time Factors | 8 | 2017 | 4655 | 0.090 |
Why?
|
| Myelitis | 1 | 2010 | 9 | 0.090 |
Why?
|
| Acute Lung Injury | 1 | 2011 | 35 | 0.090 |
Why?
|
| Colitis | 1 | 2012 | 156 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2010 | 94 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2010 | 714 | 0.090 |
Why?
|
| Chemokines | 1 | 2011 | 119 | 0.090 |
Why?
|
| Complement C4b | 1 | 2010 | 3 | 0.090 |
Why?
|
| Acepromazine | 1 | 2010 | 3 | 0.090 |
Why?
|
| Xylazine | 1 | 2010 | 5 | 0.090 |
Why?
|
| Mutation | 3 | 2005 | 1213 | 0.090 |
Why?
|
| Gene Expression | 2 | 2009 | 770 | 0.090 |
Why?
|
| Glycolysis | 2 | 2021 | 79 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2014 | 718 | 0.090 |
Why?
|
| Interleukin-8 | 1 | 2009 | 71 | 0.090 |
Why?
|
| Ischemic Preconditioning | 1 | 2009 | 31 | 0.090 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 166 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 189 | 0.080 |
Why?
|
| Random Allocation | 1 | 2010 | 442 | 0.080 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 3 | 2005 | 3 | 0.080 |
Why?
|
| Myocarditis | 1 | 2009 | 49 | 0.080 |
Why?
|
| Intestinal Mucosa | 1 | 2010 | 219 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 234 | 0.080 |
Why?
|
| Ketamine | 1 | 2010 | 57 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2009 | 149 | 0.080 |
Why?
|
| Intestinal Diseases | 1 | 2008 | 25 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 236 | 0.080 |
Why?
|
| Phenotype | 3 | 2018 | 947 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 199 | 0.080 |
Why?
|
| Cell Movement | 2 | 2017 | 630 | 0.080 |
Why?
|
| Dose-Response Relationship, Immunologic | 3 | 2015 | 31 | 0.080 |
Why?
|
| CD59 Antigens | 3 | 2014 | 30 | 0.080 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2008 | 118 | 0.080 |
Why?
|
| Arthritis, Experimental | 1 | 2007 | 38 | 0.070 |
Why?
|
| Cell Differentiation | 3 | 2018 | 1034 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 3 | 2018 | 164 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 940 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2010 | 483 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 742 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2020 | 507 | 0.070 |
Why?
|
| Visual Acuity | 2 | 2020 | 236 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 245 | 0.070 |
Why?
|
| Antigen-Antibody Complex | 1 | 2008 | 175 | 0.070 |
Why?
|
| Monocytes | 2 | 2018 | 210 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2018 | 397 | 0.070 |
Why?
|
| Rats | 2 | 2017 | 5300 | 0.070 |
Why?
|
| Adolescent | 2 | 2013 | 8912 | 0.070 |
Why?
|
| Biomarkers | 4 | 2011 | 1593 | 0.070 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2006 | 105 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2005 | 159 | 0.060 |
Why?
|
| Immunization | 2 | 2020 | 86 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 1536 | 0.060 |
Why?
|
| B7-2 Antigen | 2 | 2018 | 23 | 0.060 |
Why?
|
| CHO Cells | 1 | 2005 | 161 | 0.060 |
Why?
|
| Cricetinae | 1 | 2005 | 262 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2005 | 97 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2020 | 954 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 1 | 2006 | 296 | 0.060 |
Why?
|
| Pulmonary Alveoli | 1 | 2005 | 62 | 0.060 |
Why?
|
| Emphysema | 1 | 2005 | 32 | 0.060 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2005 | 61 | 0.060 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2020 | 117 | 0.060 |
Why?
|
| Neoplasms | 2 | 2015 | 1667 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 40 | 0.060 |
Why?
|
| Chromosomes, Human, Y | 1 | 2004 | 13 | 0.060 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2017 | 48 | 0.060 |
Why?
|
| Trans-Activators | 1 | 2005 | 237 | 0.060 |
Why?
|
| Complement Membrane Attack Complex | 2 | 2014 | 20 | 0.060 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2003 | 42 | 0.060 |
Why?
|
| Locomotion | 2 | 2017 | 135 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2020 | 110 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2013 | 7277 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 317 | 0.050 |
Why?
|
| Phosphates | 1 | 2003 | 72 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 163 | 0.050 |
Why?
|
| Polymers | 1 | 2005 | 244 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 1851 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2023 | 82 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2005 | 323 | 0.050 |
Why?
|
| Activin Receptors, Type I | 1 | 2002 | 14 | 0.050 |
Why?
|
| Gammaherpesvirinae | 1 | 2002 | 2 | 0.050 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2002 | 56 | 0.050 |
Why?
|
| Complement C1q | 2 | 2012 | 18 | 0.050 |
Why?
|
| Herpesviridae Infections | 1 | 2002 | 23 | 0.050 |
Why?
|
| Tumor Virus Infections | 1 | 2002 | 32 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2002 | 79 | 0.050 |
Why?
|
| Hepatectomy | 2 | 2014 | 58 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2002 | 37 | 0.050 |
Why?
|
| Heterozygote | 1 | 2002 | 174 | 0.050 |
Why?
|
| Young Adult | 1 | 2013 | 5717 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 168 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2022 | 114 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 786 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 700 | 0.050 |
Why?
|
| Incidence | 1 | 2005 | 1603 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2023 | 7029 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2020 | 37 | 0.050 |
Why?
|
| Nystagmus, Optokinetic | 1 | 2020 | 5 | 0.040 |
Why?
|
| Alanine Transaminase | 2 | 2011 | 137 | 0.040 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 34 | 0.040 |
Why?
|
| Contrast Sensitivity | 1 | 2020 | 28 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2017 | 329 | 0.040 |
Why?
|
| Aged | 4 | 2018 | 14862 | 0.040 |
Why?
|
| RNA | 1 | 2020 | 171 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 37 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2011 | 241 | 0.040 |
Why?
|
| Leukemia | 1 | 2020 | 117 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 126 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 190 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.040 |
Why?
|
| Cell Death | 2 | 2010 | 329 | 0.040 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2018 | 18 | 0.040 |
Why?
|
| Demyelinating Diseases | 2 | 2010 | 57 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1553 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2019 | 156 | 0.040 |
Why?
|
| Cold Ischemia | 1 | 2018 | 5 | 0.040 |
Why?
|
| Necrosis | 2 | 2011 | 239 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 377 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 567 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2018 | 31 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2018 | 41 | 0.040 |
Why?
|
| CD11b Antigen | 1 | 2018 | 47 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2018 | 147 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2018 | 104 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2018 | 93 | 0.040 |
Why?
|
| Leukocytes | 1 | 2018 | 99 | 0.040 |
Why?
|
| Interleukin-6 | 2 | 2009 | 330 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 1033 | 0.040 |
Why?
|
| Antigens | 1 | 2017 | 90 | 0.040 |
Why?
|
| Tobacco Products | 1 | 2020 | 234 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2018 | 239 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 848 | 0.040 |
Why?
|
| Autophagy | 1 | 2018 | 208 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2017 | 75 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 301 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2018 | 328 | 0.030 |
Why?
|
| CD55 Antigens | 2 | 2008 | 13 | 0.030 |
Why?
|
| Electroretinography | 1 | 2016 | 122 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2016 | 351 | 0.030 |
Why?
|
| Isografts | 1 | 2015 | 2 | 0.030 |
Why?
|
| Transplantation, Isogeneic | 1 | 2015 | 19 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2015 | 50 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 167 | 0.030 |
Why?
|
| Scotland | 1 | 2015 | 18 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 209 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2015 | 104 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 63 | 0.030 |
Why?
|
| Heart Ventricles | 3 | 2005 | 738 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2016 | 118 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2018 | 318 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 786 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 2093 | 0.030 |
Why?
|
| Microglia | 1 | 2015 | 143 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 201 | 0.030 |
Why?
|
| Hematinics | 1 | 2015 | 52 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 1027 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2014 | 21 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 756 | 0.030 |
Why?
|
| Transcription Factor CHOP | 1 | 2014 | 28 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 241 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 282 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 56 | 0.030 |
Why?
|
| Calcifediol | 1 | 2014 | 70 | 0.030 |
Why?
|
| Liver Failure, Acute | 1 | 2014 | 49 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2014 | 69 | 0.030 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 62 | 0.030 |
Why?
|
| Arginine | 1 | 2014 | 102 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 2014 | 112 | 0.030 |
Why?
|
| DNA | 1 | 2016 | 597 | 0.030 |
Why?
|
| Lectins | 1 | 2013 | 81 | 0.030 |
Why?
|
| Mitochondria, Liver | 1 | 2014 | 148 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2013 | 29 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 61 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 314 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 186 | 0.030 |
Why?
|
| Mice, Inbred ICR | 1 | 2012 | 44 | 0.030 |
Why?
|
| Complement C6 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Complement Pathway, Mannose-Binding Lectin | 1 | 2012 | 4 | 0.030 |
Why?
|
| Perfusion | 1 | 2013 | 131 | 0.030 |
Why?
|
| Kinetics | 1 | 2014 | 1047 | 0.030 |
Why?
|
| Risk Factors | 2 | 2015 | 5731 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 2358 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2012 | 26 | 0.030 |
Why?
|
| Hypoxia | 1 | 2013 | 169 | 0.030 |
Why?
|
| Dextran Sulfate | 1 | 2012 | 88 | 0.030 |
Why?
|
| Genes, RAG-1 | 1 | 2011 | 4 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2011 | 34 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 733 | 0.020 |
Why?
|
| Biological Products | 1 | 2012 | 78 | 0.020 |
Why?
|
| Lymphoma | 1 | 2012 | 116 | 0.020 |
Why?
|
| Interleukin-5 | 1 | 2011 | 14 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 92 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2011 | 20 | 0.020 |
Why?
|
| Antigens, Fungal | 1 | 2011 | 19 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 371 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 386 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 931 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 306 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2014 | 296 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 3705 | 0.020 |
Why?
|
| Nicotine | 1 | 2014 | 350 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 337 | 0.020 |
Why?
|
| Clodronic Acid | 1 | 2010 | 9 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2010 | 30 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2010 | 25 | 0.020 |
Why?
|
| Swine | 2 | 2002 | 672 | 0.020 |
Why?
|
| Anesthetics, Combined | 1 | 2010 | 2 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2012 | 215 | 0.020 |
Why?
|
| Anesthesia Recovery Period | 1 | 2010 | 11 | 0.020 |
Why?
|
| Isoflurane | 1 | 2010 | 16 | 0.020 |
Why?
|
| Anesthetics, Inhalation | 1 | 2010 | 21 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2010 | 89 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2010 | 150 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 210 | 0.020 |
Why?
|
| Endotoxins | 1 | 2009 | 76 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2009 | 103 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2334 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 86 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2009 | 75 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 230 | 0.020 |
Why?
|
| Membrane Cofactor Protein | 1 | 2008 | 7 | 0.020 |
Why?
|
| Dimerization | 1 | 2008 | 99 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 682 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3259 | 0.020 |
Why?
|
| Tumor Escape | 1 | 2008 | 37 | 0.020 |
Why?
|
| Anesthesia | 1 | 2010 | 120 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 322 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2010 | 455 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2007 | 120 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 489 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 852 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 420 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 626 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 434 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 2006 | 49 | 0.020 |
Why?
|
| Binding Sites | 1 | 2007 | 631 | 0.020 |
Why?
|
| Smad1 Protein | 1 | 2005 | 10 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2005 | 17 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2005 | 25 | 0.020 |
Why?
|
| Ammonium Sulfate | 1 | 2005 | 6 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 45 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1447 | 0.020 |
Why?
|
| Leukocyte Elastase | 1 | 2005 | 19 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2005 | 43 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 25 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2005 | 38 | 0.020 |
Why?
|
| Organ Preservation | 1 | 2005 | 69 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 40 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2005 | 43 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2005 | 49 | 0.020 |
Why?
|
| Homozygote | 1 | 2005 | 119 | 0.020 |
Why?
|
| Point Mutation | 1 | 2005 | 97 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 134 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 150 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 147 | 0.010 |
Why?
|
| Collagen | 1 | 2007 | 636 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2005 | 112 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 386 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2003 | 62 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2004 | 81 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2003 | 111 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1753 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2003 | 201 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 174 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2003 | 238 | 0.010 |
Why?
|
| Papio | 1 | 2002 | 27 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 901 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2002 | 16 | 0.010 |
Why?
|
| DNA Probes | 1 | 2002 | 57 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2002 | 31 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2002 | 63 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2003 | 172 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 216 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2003 | 383 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 411 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2002 | 133 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 1140 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 981 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1174 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 546 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1054 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 658 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 442 | 0.010 |
Why?
|